Alnylam Pharmaceuticals (ALNY) has disclosed a new risk, in the Regulation category.
Alnylam Pharmaceuticals faces significant risk if it fails to adhere to the intricate requirements of U.S. governmental pricing programs such as the 340B Drug Pricing Program. Frequent changes and ambiguous obligations under these programs necessitate diligent compliance to avoid substantial fines, penalties, and sanctions. Missteps in providing accurate pricing data or rebate payments could lead to severe repercussions, jeopardizing the company’s financial stability and future prospects. The administrative burden and potential financial impact of non-compliance underscore a material business risk for Alnylam.
Overall, Wall Street has a Moderate Buy consensus rating on ALNY stock based on 14 Buys and 8 Holds.
To learn more about Alnylam Pharmaceuticals’ risk factors, click here.
